Neuroendocrine neoplasm
MONDO:0019496Endocrine tumors, also referred to as neuroendocrine tumors (NETs), are defined by a common phenotype which is characterized by the expression of general markers (neuron specific enolase, chromogranin, synaptophysin) and hormone secretion products. These tumors may be localized in any part of the body and are generally discovered in non-specific situations, i.e. not immediately suggestive of NETs (tests for inherited predisposition to tumors or for a clinical syndrome caused by abnormal hormone secretion).
Also known as: APUDoma, neuroendocrine neoplasm, neuroendocrine tumor, neuroendocrine tumour
2350 clinical trials for this condition and its sub-types, 181 tagged with Neuroendocrine neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Neuroendocrine neoplasm
-
Neuroendocrine carcinoma 106 trials · 744 incl. sub-types
12 sub-types
- Small cell carcinoma 26 trials · 542 incl. sub-types Sub-types →
- Cutaneous neuroendocrine carcinoma 78 trials
- Medullary thyroid gland carcinoma 42 trials · 53 incl. sub-types Sub-types →
- Large cell neuroendocrine carcinoma 12 trials · 31 incl. sub-types Sub-types →
- Pancreatic endocrine carcinoma 12 trials Sub-types →
- Malignant adrenal gland pheochromocytoma 11 trials
- Liver neuroendocrine carcinoma 3 trials Sub-types →
- Thymic neuroendocrine carcinoma 3 trials Sub-types →
- Goblet cell carcinoma 2 trials
- Anal canal neuroendocrine neoplasm 1 trial Sub-types →
- Combined lung carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Vulvar neuroendocrine carcinoma 0 trials Sub-types →
-
Lung neuroendocrine neoplasm 21 trials · 540 incl. sub-types
5 sub-types
- Small cell lung carcinoma 514 trials · 515 incl. sub-types Sub-types →
- Pulmonary large cell neuroendocrine carcinoma 20 trials Sub-types →
- Lung carcinoid tumor 2 trials
- Combined lung carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Lung mixed small cell and squamous cell carcinoma 0 trials
-
Digestive system neuroendocrine neoplasm 52 trials · 167 incl. sub-types
7 sub-types
- Digestive system neuroendocrine tumor, grade 1/2 66 trials · 145 incl. sub-types Sub-types →
- Pancreatic neuroendocrine neoplasm 9 trials · 85 incl. sub-types Sub-types →
- Intestinal neuroendocrine neoplasm 7 trials · 21 incl. sub-types Sub-types →
- Gastric neuroendocrine neoplasm 3 trials · 6 incl. sub-types Sub-types →
- Liver neuroendocrine carcinoma 3 trials Sub-types →
- Gallbladder neuroendocrine neoplasm 0 trials Sub-types →
- Salivary gland small cell carcinoma 0 trials
-
Paraganglioma 53 trials · 57 incl. sub-types
12 sub-types
- Sympathetic paraganglioma 0 trials · 16 incl. sub-types Sub-types →
- Head and neck paraganglioma 1 trial Sub-types →
- Non-secreting paraganglioma 0 trials Sub-types →
- Parasympathetic paraganglioma 0 trials Sub-types →
- Pheochromocytoma/paraganglioma syndrome 1 0 trials
- Pheochromocytoma/paraganglioma syndrome 2 0 trials
- Pheochromocytoma/paraganglioma syndrome 3 0 trials
- Pheochromocytoma/paraganglioma syndrome 4 0 trials
- Pheochromocytoma/paraganglioma syndrome 5 0 trials
- Pheochromocytoma/paraganglioma syndrome 6 0 trials
- Pheochromocytoma/paraganglioma syndrome 7 0 trials
- Sporadic pheochromocytoma/secreting paraganglioma 0 trials Sub-types →
-
Carcinoid tumor 33 trials · 47 incl. sub-types
7 sub-types
- Intestinal neuroendocrine tumor G1 5 trials · 8 incl. sub-types Sub-types →
- Somatostatinoma 6 trials
- Pancreatic neuroendocrine tumor G1 1 trial · 5 incl. sub-types Sub-types →
- Atypical carcinoid tumor 4 trials
- Gastric neuroendocrine tumor G1 2 trials
- Lung carcinoid tumor 2 trials
- Childhood carcinoid tumor 0 trials
-
Prostate neuroendocrine neoplasm 20 trials · 25 incl. sub-types
1 sub-type
- Prostate small cell carcinoma 9 trials
-
9 sub-types
- MAX-related tumor predisposition 0 trials
- TMEM127-related tumor predisposition 0 trials
- Pheochromocytoma/paraganglioma syndrome 1 0 trials
- Pheochromocytoma/paraganglioma syndrome 2 0 trials
- Pheochromocytoma/paraganglioma syndrome 3 0 trials
- Pheochromocytoma/paraganglioma syndrome 4 0 trials
- Pheochromocytoma/paraganglioma syndrome 5 0 trials
- Pheochromocytoma/paraganglioma syndrome 6 0 trials
- Pheochromocytoma/paraganglioma syndrome 7 0 trials
-
Thymic neuroendocrine tumor 3 trials · 6 incl. sub-types
1 sub-type
-
Bronchial endocrine tumor 4 trials
-
Ovarian neuroendocrine neoplasm 0 trials · 2 incl. sub-types
2 sub-types
- Ovarian small cell carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Ovarian large-cell neuroendocrine carcinoma 0 trials
-
Breast neuroendocrine neoplasm 0 trials
1 sub-type
-
Laryngeal neuroendocrine neoplasm 0 trials
1 sub-type
- Laryngeal small cell carcinoma 0 trials
-
Middle ear neuroendocrine tumor 0 trials
1 sub-type
- Tympanic paraganglioma 0 trials
-
2 sub-types
Most studied deeper sub-types
-
Can a targeted drug tame neuroendocrine tumors in everyday practice?
Disease control Not yet recruitingThis study looks at how well the drug surufatinib works and how safe it is for people with neuroendocrine tumors, a type of cancer that grows from hormone-producing cells. Researchers will follow about 60 patients who receive surufatinib either alone or with other treatments, as …
Sponsor: Yefeng • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a new pill tame childhood cancers that Won't quit?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called zanzalintinib in children and teens with solid tumors that have returned or not responded to standard treatment. The main goals are to find the highest safe dose and to see how well the drug is tolerated. Participants …
Phase 1 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Experimental drug targets Hard-to-Treat neuroendocrine cancers
Disease control Not yet recruitingThis trial tests an experimental drug called CTX-471 in people with advanced neuroendocrine tumors that have a specific marker (NCAM) and have stopped responding to standard treatments. Participants receive the drug by IV every two weeks. The study aims to see if the drug can shr…
Phase 2 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial
Disease control Not yet recruitingThis phase 1 trial tests a radioactive drug called 211At-MABG in 16 adults with advanced neuroendocrine cancers, including pheochromocytoma and paraganglioma. The drug delivers radiation directly to cancer cells that show up on a special scan. The main goal is to see if the treat…
Phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for rare gut tumors? phase 2 trial launches
Disease control Not yet recruitingThis phase 2 trial tests a new drug called AUR103 calcium in 30 people with advanced neuroendocrine tumors that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing. Participants take the drug twice daily unt…
Phase 2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug aims to stop neuroendocrine tumors from returning after surgery
Disease control Not yet recruitingThis phase 2 trial tests whether the drug surufatinib, taken daily for 6 months after surgery, can prevent neuroendocrine tumors from coming back in high-risk patients. It will enroll 35 adults with stage III tumors (including G1, G2, and all G3 types). The main goal is to see ho…
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
Diagnosis Not yet recruitingThis trial is testing whether a new type of PET/CT scan, using a tracer that targets a protein called DLL3 found on many neuroendocrine tumor cells, can detect cancer spread more accurately than standard scans. About 200 adults with metastatic neuroendocrine tumors will receive b…
Phase 2 • Sponsor: Tingting Yuan • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
New imaging agent could improve detection of rare cancers
Diagnosis Not yet recruitingThis study will compare a new radioactive tracer, 18F-AmBF3TATE, to the standard tracer 68Ga-DOTATATE for PET scans in people with neuroendocrine tumors. The goal is to see if the new tracer is as good or better at finding tumors. About 51 participants will receive both tracers a…
Sponsor: British Columbia Cancer Agency • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New PET scan could sharpen detection of neuroendocrine tumors
Diagnosis Not yet recruitingThis study will test a new type of PET scan using a radioactive tracer called 18F-Octreotide in 152 people with or suspected of having neuroendocrine tumors. The goal is to see if this scan can more accurately locate tumors, guide treatment decisions, and help predict how the dis…
Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
New study aims to unlock secrets of lung cancer drug through blood tests
Knowledge-focused Not yet recruitingThis study will collect blood samples from 25 people with small cell lung cancer who are being treated with the drug tarlatamab. Researchers will analyze the samples to learn more about how the drug works, who might benefit most, and how to predict side effects like cytokine rele…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New study aims to reduce harmful side effects in rare cancer patients
Knowledge-focused Not yet recruitingThis study will follow 1,100 people with advanced neuroendocrine tumors (a rare, slow-growing cancer) to see which treatments or treatment sequences cause the fewest long-term side effects. Researchers will track patients for up to 5 years, recording any side effects that last mo…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New registry aims to unlock secrets of rare heart disease from gut tumors
Knowledge-focused Not yet recruitingThis study will create a registry of about 120 patients in Poland who have carcinoid heart disease, a rare complication of neuroendocrine tumors that damages heart valves. Researchers will collect medical records, echocardiograms, and lab results to better understand who develops…
Sponsor: National Institute of Cardiology, Warsaw, Poland • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Study to test if patient education improves side effect management for neuroendocrine tumor patients on oral therapy
Knowledge-focused Not yet recruitingThis study will enroll 100 adults with neuroendocrine tumors who are starting oral anti-cancer drugs like everolimus or sunitinib. Researchers want to see if a therapeutic education program—including questionnaires and nurse consultations—helps patients handle side effects and ma…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC